Study on COPD Corticosteroid-induced Hyperglycemia on Clinical Outcome in Patients With COPD
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Hyperglycemia is a common complication of corticosteroid (cortisone) therapy. It is estimated that more than a third of patients with chronic pulmonary disease (COPD) exacerbation (16). Despite its frequency, the impact of corticosteroid-induced diabetes on clinical outcome and mortality is not known. A computerized search of biomedical journal literature from MEDLINE, PubMed, and Ovid from 1966 to 2006 provided very little information on the prevalence and outcome of corticosteroid-induced diabetes in patients with COPD. Therefore, the present study aims to evaluate the impact of corticosteroid-induced diabetes on clinical outcome in patients with COPD exacerbation. We will perform a retrospective chart review of all patients admitted to the hospital with COPD exacerbation from 1/01/05 to 06/30/06 at Grady Memorial Hospital. Medical records of all patients with COPD exacerbation treated with corticosteroids will be analyzed. Data on demographics, laboratory values, mortality rate, rate of hypoglycemic events, length of stay, as well as disposition at discharge will be analyzed.
| Condition |
|---|
|
COPD |
| Study Type: | Observational |
| Study Design: | Time Perspective: Retrospective |
| Official Title: | The Impact of Corticosteroid-induced Hyperglycemia on Clinical Outcome (Length of Stay, Disposition, APACHE Score, Need for Ventilatory Support and ICU Admission, Mortality) in Patients With COPD Exacerbation |
- The primary outcome of the study is to determine the mortality rate of COPD patients with corticosteroid-induce hyperglycemia. [ Time Frame: once all charts have been reviews ] [ Designated as safety issue: Yes ]
| Enrollment: | 450 |
| Study Start Date: | February 2006 |
| Study Completion Date: | December 2009 |
| Primary Completion Date: | June 2009 (Final data collection date for primary outcome measure) |
Hypotheses:
We hypothesize that COPD patients with corticosteroid-induced hyperglycemia experience higher morbidity (infections, ventilator associated pneumonia, length of stay, acute renal failure) and mortality compared to COPD patients with normal glucose levels.
Specific Aim:
To determine the impact of corticosteroid-induced hyperglycemia on clinical outcome (length of stay, disposition, APACHE score, need for ventilatory support and ICU admission, mortality) in patients with COPD exacerbation.
Eligibility| Ages Eligible for Study: | 18 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
Patients admitted with COPD exacerbation at Atlanta Medical Center and Grady Memorial Hospital
Inclusion Criteria: Patients admitted with COPD exacerbation
Contacts and Locations More Information
No publications provided
| Responsible Party: | Guillermo Umpierrez, MD, Emory University School of Medicine |
| ClinicalTrials.gov Identifier: | NCT00605007 History of Changes |
| Other Study ID Numbers: | e1392, e1392 |
| Study First Received: | January 17, 2008 |
| Last Updated: | April 9, 2010 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Emory University:
|
COPD Diabetes Respiratory Disorders |
Additional relevant MeSH terms:
|
Hyperglycemia Pulmonary Disease, Chronic Obstructive Glucose Metabolism Disorders Metabolic Diseases |
Lung Diseases, Obstructive Lung Diseases Respiratory Tract Diseases |
ClinicalTrials.gov processed this record on May 23, 2013